Sangamo Therapeutics Expects FY24 GAAP Basis Total Operating Expenses Of Approximately $150M - $170M
Sangamo Therapeutics Expects FY24 GAAP Basis Total Operating Expenses Of Approximately $150M - $170M
Sangamo therapeutics预计 FY24 GAAP基础的总营业费用约为1.5亿美元至1.7亿美元。
It expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $13 million, impairment expense of approximately $6 million, and depreciation and amortization of approximately $7 million, in the range of approximately $125 million to $145 million in 2024.
预计在2024年，非GAAP总营业费用将在大约12500万至14500万区间内，不包括约1300万美元的估算非现金股票补偿费用、约600万美元的减值费用和约700万美元的折旧和摊销费用。